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Summary
 
Class I–restricted presentation is usually associated with cytoplasmic degradation of cellular pro-
teins and is often considered inaccessible to exogenous antigens. Nonetheless, certain exoge-
nous elements can gain entry into this so-called endogenous pathway by a mechanism termed
cross-presentation. This is known to be effective for class I–restricted cytotoxic T lymphocyte
(CTL) cross-priming directed against a variety of exogenous tumor, viral, and minor transplan-
tation antigens. The related effect of cross-tolerance can also effectively eliminate responses to
selected self components. In both cases, this presentation appears to require the active involve-
ment of a bone marrow–derived antigen presenting cell (APC). Here, we show that CTL in-
duction by cross-priming with cell-associated ovalbumin requires the active involvement of
CD4
 
1
 
 helper T cells. Importantly, this CD4
 
1
 
 population is only effective when both the
helper and CTL determinants are recognized on the same APC. Moreover, we would argue
that the cognitive nature of this event suggests that the CD4
 
1
 
 T cell actively modifies the APC,
converting it into an effective stimulator for the successful priming of the CTL precursor.
 
A
 
large body of evidence suggests that there is a clear de-
marcation between class I– and class II–restricted anti-
gen processing pathways. Class II–restricted antigens are
largely derived from exogenous proteins that enter APCs via
the endocytic pathway and are processed in the endosomal
compartment. By contrast, antigens recognized by class
I–restricted effector CTL are usually derived from endoge-
nously synthesized proteins. Thus, exogenous proteins can-
not provide antigenic determinants for class I–restricted
effector CTL unless they are introduced directly into the
cytoplasm of target cells (1). Presumably, this limitation en-
sures that only cells that are infected by virus, and not those
that simply ingest viral proteins, are killed by effector CTL.
The view that class I–restricted antigens must be endog-
enously derived has primarily been formed by examining
killing of target cells by effector CTL. When priming of
CTL is examined, however, there is convincing evidence that
exogenous proteins can provide a source of class I–restricted
antigens (2, 3). This was first implicated in studies examin-
ing the induction of CTL to minor histocompatibility anti-
gens and was referred to as cross-priming (2). Cross-prim-
ing has subsequently been shown to occur for viral proteins
(3), protein-coated spleen cells (4), and tumor antigens (5).
This has led to the proposal that cross-priming may provide
the immune system with a mechanism by which it can de-
tect and respond to tissue-tropic viruses that do not infect
professional APC (6). In the absence of such a mechanism,
viruses could escape immunosurveillance by avoiding pro-
fessional APC. This mechanism also provides the immune
system with a means to survey neoantigens expressed by
newly arising tumor cells (5).
Like exogenous foreign antigens (2–4), exogenous self-
antigens can enter the class I–presentation pathway (7, 8). In
contrast to foreign antigens, however, CTL immunity is not
induced (7). This means that in addition to class I–restricted
cross-presentation, other factors are required for CTL cross-
priming. In this report, we examine these requirements.
OVA-specific CTL can be induced by intravenous injec-
tion of irradiated spleen cells loaded intracytoplasmically
with whole OVA by osmotic shock (4). Despite introduc-
tion of OVA into the cytoplasm, CTL priming did not oc-
cur by direct presentation, but required cross-priming on a
bone marrow–derived host APC. This response was found
to require CD4
 
1
 
 T cell help, which had to be delivered to
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the same APCs as those seen by the CD8
 
1
 
 T cell popula-
tion. The implications for these findings with respect to
class I–restricted immunity are discussed.
 
Materials and Methods
 
Mice.
 
All mice were bred and maintained at the Walter and
Eliza Hall Institute for Medical Research. For all experiments,
mice between 8 and 16 wk of age were used. Class II–deficient
mice were a gift of Dr. Dianne Matthias (Institut National de la
Sante et de la Recherche Medicale, Strasbourg, France; reference 9).
 
CTL Priming.
 
Two protocols were used to generate OVA-
specific CTL. In the first protocol, spleen cells were loaded with
OVA by osmotic shock as previously described (1). In brief, 2 
 
3
 
10
 
8
 
 spleen cells were incubated for 10 min at 37
 
8
 
C in 1 ml of
RPMI containing 10 mg of whole OVA (grade V, catalog No.
A-5503; Sigma Chemical Co., St. Louis, MO), 25 mM Hepes,
0.5 M sucrose, and 10% polyethylene glycol 1,000. These cells
were then diluted in 14 ml of 60:40 RPMI/water for 2 min at
37
 
8
 
C before being centrifuged at 400 
 
g
 
 for 7 min. After being
washed once in Hepes Eagle’s medium (HEM)
 
1
 
, the cells were
then irradiated for 1,500 centiGrey (cGy), washed twice more,
filtered through nylon mesh to remove aggregates, counted, and
finally, injected into C57BL/6 (B6) mice at 20–25 
 
3
 
 10
 
6
 
/mouse
intravenously in 0.5 ml of HEM.
The second approach for priming OVA-specific CTL was by
subcutaneous injection of the H-2K (K)
 
b
 
-restricted, immunodomi-
nant OVA
 
257-264
 
 peptide emulsified in CFA. OVA
 
257-264
 
 peptide at
200 
 
m
 
g/ml in HEM was emulsified in an equal volume of CFA.
Mice were then injected subcutaneously with 100–200 
 
m
 
l of this
emulsion containing 10–20 
 
m
 
g of peptide.
 
In Vitro Generation of OVA-specific CTL.
 
In most experiments,
spleens were removed from primed mice 7 d after priming, and
CTL were generated as previously described (10). In brief, the
spleen cells from one spleen were washed, counted, and cultured
for 6 d in vitro in 30 ml of RPMI containing 10% FCS, 50 
 
m
 
M
2-mercaptoethanol, 2 mM 
 
l
 
-glutamine, and 10
 
7
 
 E.G7 cells that
had been irradiated for 20,000 cGy. In some cases, E.G7 cells
were replaced with 10
 
8
 
 OVA-loaded spleen cells irradiated for
1,500 cGy; this did not affect the response outcome. Their cyto-
toxicity was then assessed in a 
 
51
 
Cr–release assay using E.G7 cells,
EL4 cells alone, or EL4 cells coated with 1 
 
m
 
g/ml OVA
 
257-264
 
during 
 
51
 
Cr labeling.
 
Depletion of CD4
 
1
 
T Cells.
 
For in vivo depletion of CD4
 
1
 
 T
cells, B6 mice were thymectomized at 4 wk of age, and 2 wk later
were injected intraperitoneally with 100 
 
m
 
l of GK1.5 ascites
twice 3 d apart. One week after the first injection, mice were
primed to examine CTL induction.
For in vitro depletion of CD4
 
1
 
 T cells, spleen cells were ex-
posed to a 1:3 dilution of RL172 supernatant in HEM with 2.5%
FCS for 30 min at 4
 
8
 
C, washed once, and then exposed to a 1:8
mixture of rabbit complement (catalog No. 6004C; C-six Diag-
nostics Inc., Mequon, WI) in HEM with 10% FCS for 30 min at
37
 
8
 
C. Cells were then washed twice with HEM before in vitro
culture.
 
Generation of Bone Marrow Chimeras.
 
To generate bone mar-
row chimeras, adult mice were lethally irradiated for 900 cGy and
reconstituted with 5 
 
3
 
 10
 
6
 
 T–cell depleted bone marrow cells of
the appropriate background. The next day, mice were injected
with 100 
 
m
 
l of T24 (anti-Thy-1) ascites to deplete radioresistant
T cells. These mice were then left at least 8 wk before immuniza-
tion.
 
Flow Cytometry.
 
Cells from the blood were stained as de-
scribed (11).
 
Results
 
CTL Priming by OVA-loaded Spleen Cells Occurs by Cross-
priming.
 
OVA-specific CTL can be generated by injecting
B6 mice intravenously with irradiated, syngeneic spleen
cells that have been loaded intracytoplasmically with OVA
(OVA-loaded spleen cells; 4). Intracytoplasmic loading is
achieved by exposing spleen cells to a hypertonic solution
of OVA. Those pinosomes that were generated during this
exposure burst due to osmotic shock when the cells were
exposed to hypotonic conditions. This releases OVA into
the cytoplasm where it can be processed into the class I
pathway (1). To determine whether priming with OVA-
loaded spleen cells was due to direct presentation of OVA
by these cells, we took advantage of the fact that CTL can
be generated in B6 mice, but are not detectable in bm1
mice, which differ only at the K locus. CTL cannot be in-
duced in bm1 mice because K
 
bm1
 
, unlike K
 
b
 
, is unable to
present OVA to CD8
 
1
 
 T cells (12). (B6 
 
3
 
 bm1)F
 
1
 
 mice
were primed with either B6 or bm1 OVA-loaded spleen
cells, and then examined for CTL induction (Fig. 1). This
showed that spleen cells expressing either haplotype could
be used to prime for CTL induction, implying that host,
rather than donor, cells were responsible for antigen pre-
sentation. Thus, it appeared that host APCs somehow cap-
tured OVA antigen associated with the OVA-loaded spleen
cells and presented this to host T cells.
To determine whether the host APC responsible for an-
tigen presentation was of bone marrow origin, (B6 
 
3
 
bm1)F
 
1
 
 chimeric mice were generated in which the bone
marrow compartment was either from B6 or bm1 mice
and, therefore, either able or unable to present OVA to
CD8
 
1
 
 T cells, respectively. When these chimeric mice were
primed with bm1 OVA-loaded spleen cells, OVA-specific
CTL were only generated when the bone marrow com-
partment was of B6 origin (Fig. 2 
 
a
 
). This indicated that a
bone marrow–derived APC of host origin was responsible
 
1
 
Abbreviations used in this paper:
 
 cGy, centiGrey; K, H-2K; HEM, Hepes
Eagle’s medium.
Figure 1. OVA-loaded spleen
cells prime by cross-presentation
on host APCs. (B6 3 bm1)F1
mice were injected intravenously
with 2.5 3 107 B6 (circles) or
bm1 (squares) OVA-loaded
spleen cells. 7 d later, their
spleens were removed and stim-
ulated in vitro with OVA-
loaded, irradiated splenocytes.
After 6 d, a chromium release as-
say using OVA257-264-pulsed EL4
(closed symbols) and EL4 (open sym-
bols) targets was performed. This
experiment was performed three
times with 2–4 mice/group. 
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for capturing exogenous OVA and presenting it in the class
I presentation pathway for the generation of OVA-specific
CTL. In support of the conclusion that presentation must
proceed through a host APC, there was no CTL genera-
tion when bm1 bone marrow into (B6 
 
3
 
 bm1)F
 
1
 
 chimeras
were primed with B6 OVA-loaded spleen cells, even
though donor spleen cells expressed the correct MHC hap-
lotype for direct presentation of OVA (Fig. 2 
 
b
 
).
The results presented so far are consistent with the find-
ings of Carbone and Bevan (4), who showed that priming
with protein-coated spleen cells could generate CTL by cross-
priming.
 
OVA-specific Cross-priming Requires CD4
 
1
 
 T Cell Help.
 
To determine whether CD4
 
1
 
 T cell help was required for
the generation of OVA-specific CTL by cross-priming
with OVA-loaded spleen cells, this response was examined
in CD4
 
1
 
 T cell–depleted B6 mice (Fig. 3 
 
a
 
). The failure to
generate OVA-specific CTL under these conditions indi-
cated that CD4
 
1
 
 T cells were essential for CTL priming.
This requirement was only apparent for in vivo priming,
since depletion of CD4
 
1
 
 T cells during the in vitro culture
period did not prevent the generation of CTL (Fig. 3 
 
b
 
).
It was also possible to prime K
 
b
 
-restricted OVA-specific
CTL by subcutaneous injection of OVA
 
257-264
 
 peptide emul-
sified in CFA. This response was, however, not dependent
on CD4
 
1
 
 T cell help (Fig. 4).
 
Cognate CD4
 
1
 
 T Cell Help Is Required for the Generation of
OVA-specific CTL by OVA-loaded Spleen Cell Priming.
 
To investigate the basis of CD4
 
1
 
 T cell help, we asked
whether CD4
 
1
 
 and CD8
 
1
 
 T cells had to see OVA on the
same APC. (B6 
 
3
 
 bm1)F
 
1
 
 mice were reconstituted with
equal amounts of two types of bone marrow: bm1 bone
marrow, and class II knockout B6 bone marrow. This gen-
erated a mixture of bm1 APCs that could present OVA to
CD4
 
1
 
 but not CD8
 
1
 
 T cells, and class II–deficient APCs
that could present OVA to CD8
 
1
 
 but not CD4
 
1
 
 T cells.
When these mice were primed with OVA-loaded spleen
cells, there was no induction of OVA-specific CTL (Fig. 5 
 
a
 
).
This suggested that CD4
 
1
 
 and CD8
 
1
 
 T cells needed to
recognize antigen on the same APC. OVA-loaded spleen
cell priming used in this experiment was shown to be effec-
tive, since it primed for CTL in mice reconstituted with
(B6 
 
3
 
 bm1)F
 
1
 
 bone marrow, which contain APCs capable
of presenting to both CD4
 
1
 
 and CD8
 
1
 
 T cells (Fig. 5 
 
b
 
).
To show that the mixed bone marrow chimeras had
been properly reconstituted, these mice were primed with
OVA
 
257-264
 
 peptide in CFA and examined for CTL induc-
tion (Fig. 5 
 
c
 
). As shown above, this form of priming in-
duces OVA-specific CTL in the absence of CD4
 
1
 
 T cell
help (Fig. 4). Induction of CTL in the mixed bone marrow
chimeras indicated that their T cell compartment had been
successfully reconstituted. To show that class II–deficient
and bm1 bone marrow–derived APCs were both present,
the blood of chimeric mice was examined by flow cytome-
Figure 3. OVA-specific cross-priming requires CD41 T cell help in
vivo. Normal B6 mice (circles) or mice depleted of CD41 T cells by twice
weekly intraperitoneal injections of GK1.5 ascites (squares) were immu-
nized intravenously with 2.5 3 107 OVA-loaded spleen cells. 7 d later,
their spleens were removed and either left intact (a) or depleted of CD41
T cells by treatment with RL172 antibody and complement (b). After 6 d
in vitro stimulation with OVA-loaded spleen cells, a CTL assay using
OVA257-264-pulsed EL4 (closed symbols) and EL4 (open symbols) targets was
performed. This experiment was performed four times with 2–3 mice/
group.
Figure 2. The host APC responsible for cross-presentation is bone
marrow derived. (B6 3 bm1)F1 mice were lethally irradiated, reconsti-
tuted with B6 (circles) or bm1 (squares) bone marrow and, 8 wk later, were
injected intravenously with 2.5 3 107 OVA-loaded bm1 (a) or B6 (b)
spleen cells. 7 d later their spleens were removed and stimulated in vitro
for 6 d before being tested in a chromium release assay using OVA257-264-
pulsed EL4 (closed symbols) and EL4 (open symbols) targets. One of seven
mice reconstituted with bm1 bone marrow and primed with B6 OVA-
loaded spleen as represented in Fig. 2 b responded above background,
maximizing at 26% OVA-specific lysis; no response was detected by the
other six mice tested. This experiment was performed three times with 1–3
mice/group.
Figure 4. OVA-specific CTL
induction by OVA257-264 in CFA
is not dependent on CD41 T
cell help. Normal B6 mice (cir-
cles) or mice depleted of CD41 T
cells by twice weekly intraperito-
neal injection of GK1.5 ascites
(squares) were immunized subcu-
taneously with 20 mg OVA257-264
emulsified in 200 ml CFA. After
7 d, their spleens were removed
and stimulated for 6 d in vitro
before a chromium release assay
using OVA257-264-pulsed EL4
(closed symbols) and EL4 (open symbols) targets was performed. This experi-
ment was performed four times with 1–3 mice/group.68 CTL Induction by Cross-priming Requires Cognate CD4 Help
try for coexpression of class II and B220 (Fig. 6). Detection
of both class II negative and positive B2201 cells indicated
that both bone marrow types were present in the reconsti-
tuted animals.
Discussion
In this report, we show that induction of CTL by prim-
ing with OVA-loaded spleen cells occurs by cross-priming
on host bone marrow–derived APCs. Indeed, we found
that OVA-loaded splenocytes were unable to present OVA
directly to host T cells and prime a specific CTL response.
Admittedly, this absence could represent a peculiarity of
the mode of antigen delivery, specifically hypertonic load-
ing versus a more traditional mechanism such as inocula-
tion using infectious virus. However, it has been shown
that the selective depletion of macrophages could effec-
tively eliminate influenza-specific CTL priming (13), even
though macrophages do not represent the primary target of
viral replication. Such a result would be generally consis-
tent with the data presented here and suggests that cross-
presentation may represent a general mechanism involved
in CTL priming. Moreover, the involvement of a cross-
presenting APC in viral responses would provide an effec-
tive means of CTL priming within the secondary lymphoid
compartment in the absence of active synthesis of the target
antigen, as would occur in cases where viruses show tro-
pisms that do not include lymphoid tissues.
The central role for the APC in priming may explain how
helper T cell responses augment the process of CTL prim-
ing. There are numerous examples of CD41 T cell depen-
dent or quasi-dependent CTL responses. The CTL response
to minor histocompatibility antigens (14, 15) as well as re-
sponses that lead to allograft rejection (16) appear to be
CD41 T cell dependent. Even in viral-specific CTL re-
sponses, which often do not require CD41 T cell help (17–
20), there is a reduction or progressive loss of memory
CTL in the absence of helper T cells (21, 22). This suggests
that even in responses that can occur in the absence of
CD41 T cells, these helper cells may be able to provide im-
portant functions. Here we show that CTL priming with
OVA-loaded spleen cells is CD41 T cell dependent and, more
importantly, that these CD41 helper T cells must recognize
antigen on the same APC as those seen by the CD81 T cell
population. The possible existence of such cognate CD41
T cell–dependent recognition has been raised in other
studies (23–26). Keene and Forman (23) provided perhaps
the most elegant demonstration that the helper T cell and
the CTL precursor must see the same APC, but they ex-
amined the response to the alloantigen Qa1, leaving open
the possibility that such cognate help was only required for
this unusual antigen. Other reports either examined the re-
sponse of primed T cells or failed to demonstrate a true role
for each of the three cells involved in this interaction,
merely showing that a helper determinant was important
for CTL induction. Rock (27) suggested that class II–restricted
T cell help was important for induction of CTL in response
to OVA bound to latex beads, but did not address whether
this must take place on the same APC as seen by the CD81
T cells. Shirai et al. (28) demonstrated a requirement for di-
rect linkage between helper and CTL epitopes for success-
ful peptide vaccination. However, this determinant-linkage
requirement simply implied a need for cooperation be-
tween helper and cytotoxic T cells, and left undefined the
mechanism underlying this event. Therefore, our results
represent the first direct evidence that CTL induction by
cross-priming involves cognate recognition by CD41
helper T cells of a central bone marrow–derived APC that
must also be seen by the CD81 T cell.
In addition to the already reported CTL cross-priming
phenomenon, we have recently shown that cross-presenta-
tion is effective in terms of the constitutive presentation of
self-antigens (8). However, this self presentation, which
occurred in the absence of any obvious T cell help, ulti-
mately led to CTL tolerance (28a). Together with the
demonstration here that CD41 T cell help is required for
effective CTL priming, this suggests that the underlying
helper T cell requirement may play a key role in immune
surveillance, primarily focusing CTL responses towards
nonself components and avoiding harmful antiself responses.
The involvement of the APC and the essential requirement
for cognate CD41 T cell help in the induction of CTL im-
munity, suggests that the immune system has developed an
Figure 5. OVA-specific cross-presentation requires cognate CD41 T
cell help. (B6 3 bm1)F1 mice were lethally irradiated and reconstituted
with either equal parts of H-2A2/2 (class II–deficient) and bm1 bone
marrow (a and c) or (B6 3 bm1)F1 bone marrow alone (b). 8 wk later,
these mice were immunized with 2.0 3 107 OVA-loaded bm1 spleen
cells intravenously (a and b) or 10 mg OVA257-264 in 100 ml CFA subcuta-
neously (c). After 1 wk, their spleen cells were stimulated in vitro for 6 d
and a chromium release assay using OVA257-264-pulsed EL4 (closed symbols)
and EL4 (open symbols) targets was performed. This experiment was per-
formed twice with 2–3 mice/group.
Figure 6. Both class II–defi-
cient B6 and class II–sufficient
bm1 bone marrow–derived
APCs were present in the mixed
bone marrow chimeras. Flow
cytometry was performed on
the peripheral blood of all mice
before immunization for studies
shown in Fig. 5.69 Bennett et al.
intricate mechanism to prevent inappropriate CD81 CTL
responses. First, the antigen must be in a form accessible to
the cross-presenting APC, such as cell-associated debris, or
particulate in nature (29, 30). Second, CTL induction by
cross-priming can only occur if a second population of T
cells, the helper cells, are also able to recognize antigen.
The process by which helper T cells contribute to cross-
priming remains unknown. One possibility is that they
provide local lymphokines such as IL-2 for CTL expansion.
However, we favor the view that they alter the APC in
some way so that it becomes stimulatory for CD81 T cells.
Indeed, access to other mechanisms that modify APC func-
tion may form the basis of CD41 T cell–independent CTL
priming. For example, as noted above, many antiviral CTL
responses contain a considerable component that is largely
helper T cell independent. This could arise as a conse-
quence of some inherent ability of these infectious patho-
gens to directly activate APC. This would also explain why
CD41 T cell–independent CTL priming by peptide anti-
gens requires the use of strong microbial adjuvants such as
CFA. Alternatively, however, cross-priming may use an
APC population completely different from that responsible
for activation of CD81 T cells in CD41 T cell–indepen-
dent responses. The details of how the cross-priming APC
is activated, as well as the underlying mechanism that per-
mits normally exogenous antigen to enter the otherwise
endogenous class I presentation pathway remain to be de-
termined. Elucidating these functions may provide a better
understanding of the interaction between pathogens and
the immune system, and will be of benefit in the develop-
ment of more effective vaccines.
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